Prognostic Significance of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Oncologic Outcomes of Esophageal Cancer: A Systematic Review and Meta-analysis

Annals of Surgical Oncology

Volumn 23, Issue 2, 2016, Pages 646-654

  Yodying, Hariruk ^a,b   Matsuda, Akihisa ^a   Miyashita, Masao ^a   Matsumoto, Satoshi ^a   Sakurazawa, Nobuyuki ^a   Yamada, Marina ^a   Uchida, Eiji ^b,c  

^a NIPPON MEDICAL SCHOOL CHIBA HOKUSOH HOSPITAL   (Japan)

^b SRINAKHARINWIROT UNIVERSITY   (Thailand)

^c NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CHEMORADIOTHERAPY; COHORT ANALYSIS; DATA BASE; DISEASE FREE SURVIVAL; ESOPHAGUS CANCER; ESOPHAGUS SURGERY; HUMAN; LYMPH NODE METASTASIS; META ANALYSIS; NEUTROPHIL LYMPHOCYTE RATIO; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLATELET LYMPHOCYTE RATIO; PREDICTIVE VALUE; RETROSPECTIVE STUDY; SYSTEMATIC REVIEW; TUMOR INVASION; CANCER STAGING; ESOPHAGEAL NEOPLASMS; LYMPHOCYTE; MULTIMODALITY CANCER THERAPY; NEUTROPHIL; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; THROMBOCYTE;

BLOOD PLATELETS; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; HUMANS; LYMPHOCYTES; NEOPLASM STAGING; NEUTROPHILS; PROGNOSIS; SURVIVAL RATE;

EID: 84958177341     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-015-4869-5     Document Type: Article

References (53)

1. Refaely Y, Krasna MJ. Multimodality therapy for esophageal cancer. Surg Clin North Am. 2002;82:729–46.
2. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12:681–92.
3. Paul S, Altorki N. Outcomes in the management of esophageal cancer. J Surg Oncol. 2014;110:599–610.
4. Rice TW, Rusch VW, Ishwaran H, Blackstone EH; Worldwide Esophageal Cancer Collaboration. Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer staging manuals. Cancer. 2010;116:3763–73.
5. Blanchard P, Quero L, Hennequin C. Prognostic and predictive factors of oesophageal carcinoma. Bull Cancer. 2009;96:379–89.
6. Chen M, Cai E, Huang J, Yu P, Li K. Prognostic value of vascular endothelial growth factor expression in patients with esophageal cancer: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012;21:1126–34.
7. Wang XL, Zhang CM, Shi LY, Yu HP, Xu SQ. Significance of p53 gene mutation and P53 protein expression abnormality on the prognosis of esophageal cancer: a meta-analysis study. Zhonghua Liu Xing Bing Xue Za Zhi. 2004;25:769–74.
8. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883–99.
9. Feng JF, Huang Y, Chen QX. Preoperative platelet lymphocyte ratio (PLR) is superior to neutrophil lymphocyte ratio (NLR) as a predictive factor in patients with esophageal squamous cell carcinoma. World J Surg Oncol. 2014;12:58.
10. Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, Hermanns T et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014;23:1204–12.
11. Chen H, He J. Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after radical resection of esophageal squamous cell carcinoma. Zhonghua Zhong Liu Za Zhi. 2014;36:294–7.
12. Smith RA, Ghaneh P, Sutton R, Raraty M, Campbell F, Neoptolemos JP. Prognosis of resected ampullary adenocarcinoma by preoperative serum CA19-9 levels and platelet–lymphocyte ratio. J Gastrointest Surg. 2008;12:1422–8.
13. Stotz M, Gerger A, Eisner F, Szkandera J, LoibnerH, Ress AL et al. Increased neutrophil–lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer. 2013;109:416–21.
14. Dutta S, Crumley AB, Fullarton GM, Horgan PG, McMillan DC. Comparison of the prognostic value of tumour- and patient-related factors in patients undergoing potentially curative resection of oesophageal cancer. World J Surg. 2011;35:1861–6.
15. Feng JF, Huang Y, Liu JS. Combination of neutrophil lymphocyte ratio and platelet lymphocyte ratio is a useful predictor of postoperative survival in patients with esophageal squamous cell carcinoma. Oncol Targets Ther. 2013;6:1605–12.
16. Miyata H, Yamasaki M, Kurokawa Y, Takiguchi S, Nakajima K, Fujiwara Y et al. Prognostic value of an inflammation-based score in patients undergoing pre-operative chemotherapy followed by surgery for esophageal cancer. Exp Ther Med. 2011;2:879–85.
17. Sharaiha RZ, Halazun KJ, Mirza F, Port JL, Lee PC, Neugut AI et al. Elevated preoperative neutrophil:lymphocyte ratio as a predictor of postoperative disease recurrence in esophageal cancer. Ann Surg Oncol. 2011;18:3362–9.
18. Xie X, Luo KJ, Hu Y, Wang JY, Chen J. Prognostic value of preoperative platelet–lymphocyte and neutrophil–lymphocyte ratio in patients undergoing surgery for esophageal squamous cell cancer. Dis Esophagus. 2014. doi:10.1111/dote.12296.
19. Yoo EJ, Park JC, Kim EH, Park CH, Shim CN, Lee HJ et al. Prognostic value of neutrophil-to-lymphocyte ratio in patients treated with concurrent chemoradiotherapy for locally advanced oesophageal cancer. Dig Liver Dis. 2014;46:846–53.
20. Rashid F, Waraich N, Bhatti I, Saha S, Khan, RN, Ahmed J et al. A pre-operative elevated neutrophil: lymphocyte ratio does not predict survival from oesophageal cancer resection. World J Surg Oncol. 2010;8:1.
21. Tanoglu A, Karagoz E, Yiyit N, Berber U. Is combination of neutrophil to lymphocyte ratio and platelet lymphocyte ratio a useful predictor of postoperative survival in patients with esophageal squamous cell carcinoma? Oncol Targets Ther. 2014;7:433–4.
22. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8:336–41.
23. Wells GA, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed January 5, 2015.
24. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–34.
25. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16. http://www.trialsjournal.com/content/8/1/16. Accessed January 5, 2015.
26. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.
27. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.
28. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–63.
29. Feng JF, Huang Y, Zhao Q, Chen QX. Clinical significance of preoperative neutrophil lymphocyte ratio versus platelet lymphocyte ratio in patients with small cell carcinoma of the esophagus. ScientificWorldJournal. 2013;2013:504365.
30. Feng JF, Huang Y, Chen QX. The combination of platelet count and neutrophil lymphocyte ratio is a predictive factor in patients with esophageal squamous cell carcinoma. Transl Oncol. 2014;7:632–7.
31. Ying HQ, Deng QW, He BS, Pan YQ, Wang F, Sun HL et al. The prognostic value of preoperative NLR, d-NLR, PLR and LMR for predicting clinical outcome in surgical colorectal cancer patients. Med Oncol. 2014;31:305.
32. Zhang W, Yu C, Huang B, Zhou FL, Huang HD, Li Q. Correlation between bone metastasis and thrombocytosis in pulmonary adenocarcinoma patients. Oncol Lett. 2015;9:762–8.
33. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–45.
34. Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost. 2011;9:237–49.
35. Alexandrakis MG, Passam FH, Moschandrea IA, Christophoridou AV, Pappa CA, Coulocheri SA et al. Levels of serum cytokines and acute phase proteins in patients with essential and cancer-related thrombocytosis. Am J Clin Oncol. 2003;26:135–40.
36. Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S et al. Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol. 2002;9:287–91.
37. Guo T, Krzystanek M, Szallasi Z, Szallasi A. Thrombocytosis portends adverse prognostic significance in patients with stage II colorectal carcinoma. F1000Res. 2014;3:180.
38. Zheng TL, Cao K, Liang C, Zhang K, Guo HZ, Li DP et al. Prognostic value of C-reactive protein in esophageal cancer: a meta-analysis. Asian Pac J Cancer Prev. 2014;15:8075–81.
39. Huang XZ, Gao P, Sun JX, Song YX, Tsai CC, Liu J et al. Aspirin and nonsteroidal anti-inflammatory drugs after but not before diagnosis are associated with improved breast cancer survival: a meta-analysis. Cancer Causes Control. 2015;26:589–600.
40. Voutsadakis IA. Thrombocytosis as a prognostic marker in gastrointestinal cancers. World J Gastrointest Oncol. 2014;6:34–40.
41. Lieberman MD, Shriver CD, Bleckner S, Burt M. Carcinoma of the esophagus. Prognostic significance of histologic type. J Thorac Cardiovasc Surg. 1995;109:130–8.
42. Mariette C, Taillier G, Van Seuningen I, Triboulet JP. Factors affecting postoperative course and survival after en bloc resection for esophageal carcinoma. Ann Thorac Surg. 2004;78:1177–83.
43. Zhang HL, Chen LQ, Liu RL, Shi YT, He M, Meng XL et al. The number of lymph node metastases influences survival and International Union Against Cancer tumor–node–metastasis classification for esophageal squamous cell carcinoma. Dis Esophagus. 2010;23:53–8.
44. Cho JW, Choi SC, Jang JY, Shin SK, Choi KD, Lee JH et al. Lymph node metastases in esophageal carcinoma: an endoscopist’s view. Clin Endosc. 2014;47:523–9.
45. Alkhouri N, Morris-Stiff G, Campbell C, Lopez R, Tamimi TAR, Yerian L et al. Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease. Liver Int. 2012;32:297–302.
46. Nozoe T, Saeki H, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg. 2001;182:197–201.
47. Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, Aoki T et al. Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol. 2003;83:248–52.
48. Zingg U, Forberger J, Rajcic B, Langton C, Jamieson GG. Association of C-reactive protein levels and long-term survival after neoadjuvant therapy and esophagectomy for esophageal cancer. J Gastrointest Surg. 2010;14:462–9.
49. Luc G, Durand M, Chiche L, Collet D. Major post-operative complications predict long-term survival after esophagectomy in patients with adenocarcinoma of the esophagus. World J Surg. 2015;39:216–22.
50. Rizk NP, Bach PB, Schrag D, Bains MS, Turnbull AD, Karpeh M et al. The impact of complications on outcomes after resection for esophageal and gastroesophageal junction carcinoma. J Am Coll Surg. 2004;198:42–50.
51. Balta S, Cakar M, Demirkol S, Arslan Z, Akhan M. Higher neutrophil to lymhocyte ratio in patients with metabolic syndrome. Clin Appl Thromb Hemost. 2013;19:579.
52. Karaman M, Balta S, Seyit Ahmet AY, Cakar M, Naharci I, Demirkol S et al. The comparative effects of valsartan and amlodipine on vWf levels and N/L ratio in patients with newly diagnosed hypertension. Clin Exp Hypertens. 2013;35:516–22.
53. Malietzis G, Giacometti M, Kennedy RH, Athanasiou T, Aziz O, Jenkins JT. The emerging role of neutrophil to lymphocyte ratio in determining colorectal cancer treatment outcomes: a systematic review and meta-analysis. Ann Surg Oncol. 2014;21:3938–46.